General information

Mice:  C57BL/6

The human mutant (G2019S) LRRK2 protein is expressed under the control of a mini version of the neuronal specific promoter Thy1.2.

Endogenous LRRK2: yes

Corresponding human genotype: The G2019S substitution in the LRRK2 gene is believed to be the most common mutation associated with Parkinson’s disease. It is located in the kinase domain of the protein.

Targeted gene: LRRK2

References:  Garcia-Miralles 2015

Transgene expression

  • 4 and 11 months: The total level of LRRK2 protein is 2 fold higher than the level measured in the brain of non-transgenic animals. Expression is found at high level in the cortex and hippocampus but no expression of the human mutated LRRK2 protein can be detected in the SN.


  • 12-13 months: No obvious neurodegeneration is observed in the SN.

Dopamine Homeostasis

  • Not reported


  • 11 months: No differences in the levels of alpha-synuclein is detected in the brain of transgenic animals.

Motor Behaviours

  • Not reported

Response to dopaminergic treatment

  • Not reported

Non-motor Behaviours

  • Not reported


  • Not reported


  • Not reported